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Abstract
We report the case of a 58-year-old Caucasian woman who presented with a subacute cerebellar syndrome accompanied
by disturbance of the hypothalamic–pituitary axis and was diagnosed with isolated neurosarcoidosis based on radiological
findings including typically located cerebral lesions (infratentorial and pituitary stalk). Due to persistent clinical and
radiological disease activity during several years despite escalation of immunosuppressive treatment, the diagnosis was
reevaluated, and a transsphenoidal biopsy of a lesion at the pituitary stalk was performed revealing Langerhans cell his-
tiocytosis. In this case, we discuss the different steps leading to the diagnostic error, as well as the presence of red flags,
which should have led to an earlier diagnostic reevaluation.
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Case description
A 58-year-old Caucasian woman was referred in August
2014 because of a slowly progressive cerebellar syndrome
(dizziness, ataxia, dysmetria, and dysarthria) with initial
manifestation in April 2014 accompanied by executive def-
icits and hypersomnia with additional disturbance of the
hypothalamic–pituitary axis (HPA). Cranial magnetic reso-
nance imaging showed patchy hyperintense to Fluid-
attenuated inversion recovery (FLAIR)-hyperintense lesions
with gadolinium uptake bilaterally along the middle
cerebellar peduncle and faint pial enhancement along the
midbrain (Figure 1(a)) and the hypothalamus as well as
thickening of the pituitary stalk (Figure 1(b) and (c)). Thor-
acoabdominal computer tomography (CT) and fluorodeox-
yglucose positron emission tomography (FDG-PET) did not
provide any evidence for any extra-cerebral lesions.
Repeated examination of cerebrospinal fluid (CSF) showed
slightly increased protein (0.48 g/l) and non-CSF-specific
oligoclonal bands (1 cell/ul; glucose, lactate levels unre-
markable). Due to the infratentorial distribution of the par-
enchymal white matter lesions, as well as the involvement of
the HPA, isolated neurosarcoidosis was suspected. However,
lysozyme, angiotensin-converting enzyme (ACE) and solu-
ble interleukin-2 receptor (sIL-2R) were not elevated in the
serum, and C-reactive protein levels were within normal
range. Because of low cellularity in CSF, flow cytometry
with T-lymphocyte ratio was not conclusive.
After an initially positive response to intravenous ster-
oids (size reduction of the lesions, clinical improvement),
the patient developed severe cushingoid glucocorticoster-
oid side effects under long-term prednisolone therapy,
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requiring steroid-sparing immunosuppressive treatment
with methotrexate from February 2015 and infliximab from
March 2016. Despite therapeutic escalation (up to 1000 mg
infliximab intravenous every 4 weeks), she continued to
show clinical and radiological signs of significant disease
activity and prednisolone could not be tapered off (due to
disease activity, secondary adrenal gland insufficiency, and
a disease-mediated hypopituitarism). Notably, radiological
evaluation of chest pain in January 2016 led to the iden-
tification of an osteolytic rib lesion of unknown origin and
dignity. Unfortunately, despite two consultations in which
the benefit and importance of a diagnostic workup were
emphasized, the patient refused to undergo a diagnostic
biopsy after the informed consent discussion at the radi-
ology department. However, follow-up of the lesion did
show neither metabolic activity nor a local progression or
evidence for new lesions. In July 2016, methotrexate had
to be stopped due to elevated liver enzymes and was
shortly replaced by leflunomide (stopped in October
2016 because of stomatitis). However, due to clinical and
radiological deterioration with the appearance of new cer-
ebellar lesions, methotrexate was restarted in July 2017.
Despite combined immunosuppressive treatment with
infliximab, methotrexate, and prednisolone, the patient
showed only temporary amelioration and repeated radi-
ological progress, while she developed numerous infec-
tions and endocrine side effects of these medications
(corticotropic insufficiency, Cushing syndrome, and
recurrent bilateral pyelonephritis). Additionally, as the
course of the disease evolved, clinical evaluation became
increasingly difficult due to a functional neurological
component. Finally, in March 2018, considering the per-
sistent significant disease activity and side effects of the
inefficient therapy, as well as the most likely irreversible
panhypopituitarism, a transsphenoidal biopsy of the lesion
at the pituitary stalk was performed.
Histologically, the biopsy showed fibrotic tissue with a
lymphohistiocytic infiltrate (Figure 2(a)), but no granulo-
mas. Morphological evaluation was limited due to extensive
crush artifacts. With this limitation, no histiocytic cells with
nuclear grooves or eosinophils were identified, but immuno-
histochemistry for CD1a (Figure 2(b)) and Langerin (not
shown) showed extensive staining in a pattern consistent
with Langerhans cells. Next-generation sequencing
(Ion AmpliSeq Oncomine Focus Fusion Panel) revealed a
specific mutation in the serine/threonine-protein kinase
B-Raf (BRAF V600E) as sole molecular alteration, corro-
borating a diagnosis of Langerhans cell histiocytosis (LCH).
Figure 1. T1-weighted Gd-enhanced magnetization-prepared
rapid gradient echo sequences (TR 2530 ms, TE 2.96 ms, FoV r250
mm, voxel size 1.0 1.0 1.0 mm3, acquisition time 4:30 min 160
slices) revealed multifocal patchy enhancement along the mid-
cerebellar peduncles (a), faint pial enhancement along the
mesencephalon (c), and thickening of the pituitary stalk with
expansion of the optic chiasm ((b) and (c)).
Figure 2. Histologically, the biopsy showed a dense lymphohis-
tiocytic infiltrate (a). Morphological interpretation was limited by
extensive crush artifacts, but there was extensive CD1a immu-
nostaining (b), consistent with the presence of abundant Langer-
hans cells.
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Based on an interdisciplinary discussion and the pres-
ence of the BRAF V600E mutation treatment with cladri-
bine was intended. However, the patient unexpectedly died
in May 2018 at home without the presence of any witnesses
and before the treatment was initiated. Unfortunately, the
cause of death remains unknown because no consent for an
autopsy was obtained from the next of kin.
LCH features
Langerhans cells derive from myeloic progenitor cells of
the bone marrow.1 LCH is a rare clonal proliferative dis-
order of the dendritic cell system, characterized by abnor-
mal interaction of pathologic Langerhans cells with T-cells
and chronic inflammation.2 Despite the predilection for
bone structures leading to osteolytic lesions, proliferating
cells may infiltrate almost any organ (with the exception of
kidneys and heart) and can present as isolated lesion, single
organ, or multisystem disease. Involvement of the central
nervous system (CNS) is rare (6% at diagnosis), is most
often found in patients with multisystem disease, and may
result from an extension or propagation of osteolytic
lesions of the neuro- or viscerocranium (sphenoid, orbital,
and ethmoid, temporal).3 The most common clinical man-
ifestation is hypopituitarism following infiltration of the
pituitary gland, which can be the initial clinical presenta-
tion.4 Involvement of other CNS structures mostly occurs
later during the course of the disease.5
There are no universally accepted international guide-
lines available for the treatment of adult LCH patients;
however, there are experts’ recommendations that serve
as a guide in the treatment.6 Treatment in LCH patients
should be based on the site and extension of the disease.
The specific management of CNS-LCH includes che-
motherapy that crosses the blood–brain barrier, radiation,
or a combination of both. It has been reported that several
agents are efficient in neurological forms of LCH such as
cladribine, vinblastine, prednisone, methotrexate, and
cytarabine with or without vincristine.1,7–9 In addition,
retinoic acid and intravenous immunoglobulin associated
to chemotherapy may stabilize neurodegenerative
lesions.10,11 Starting therapy with cladribine or cytarabine
seems nowadays the most adequate approach for CNS-
LCH. Several retrospective cases and one prospective trial
have demonstrated that patients harboring BRAF V600E
mutations can be effectively treated with vemurafenib or
dabrafenib.12 Furthermore, unlike pediatric recommenda-
tions, radiotherapy is an effective treatment option with
acceptable side effects for adult patients in selected situa-
tions. Proper replacement of hormonal deficiencies should
always be considered.
Diagnostic error and red flags
Here we present a case of atypical clinical and radiological
presentation of LCH, which was diagnosed and treated as
an isolated neurosarcoidosis for several years. This case
underlines the need for a repetitive reevaluation of a sus-
pected diagnosis, as long as the diagnosis is not histologi-
cally proven and especially in the case of rare diseases and
an incomplete therapeutic response. In our case, the pres-
ence of an unexplained lytic lesion in the rib should have
caused an earlier thorough reevaluation of the underlying
disease. Elements leading to the initial misdiagnosis of
neurosarcoidosis were mainly the atypical clinical and
radiological presentation with early isolated CNS manifes-
tation including primarily extensive infratentorial parench-
ymal lesions. Neurologic symptoms represent the first
defining manifestation of sarcoidosis in 50–70% of
cases,13,14 while involvement of CNS structures in LCH
mostly occurs later during the course of the disease.15 How-
ever, recent evidence suggests that CNS involvement in
LCH could be underestimated due to discrete neurological
symptoms.5 As in our case, radiologically, neurosarcoido-
sis typically presents with multiple or solitary, mainly
infratentorial lesions with T2 prolongation and post-
contrast enhancement, as well as leptomeningeal involve-
ment.16,17 This lesion pattern is thought to be secondary to
spread of inflammation from the leptomeninges along
Virchow-Robin spaces18,19 and can lead to involvement
of skull base structures, in particular the HPA.20 Intraaxial
manifestations of LCH involve multiple white matter
lesions with radiological characteristics resembling those
of neurosarcoidosis but mostly supratentorial, as well as
bilateral symmetric infratentorial gray matter lesions of the
dentate nucleus of the cerebellum or basal ganglia leading
to cerebellar symptoms and cognitive deficits.5 Our patient
presented supra- and infratentorial white matter lesions
compatible with neurosarcoidosis, however lacking the
classical leptomeningeal involvement. The HPA was
involved with several lesions of the hypothalamus and
pituitary stalk, which has been described in up to 50% of
patients with LCH15,19 and 18% of patients with
neurosarcoidosis.20
Finally, isolated CNS manifestation with disseminated
predominantly infratentorial parenchymal white matter
lesions together with the higher prevalence of sarcoidosis
(100–200 per 1,000,000 population vs. 1–2 per 1,000,000
population for LCH21,22) pointed to neurosarcoidosis as the
most likely diagnosis. To our knowledge, only one case of
late-onset LCH presenting with cerebellar ataxia as an
initial symptom has previously been described.23 Alterna-
tive radiological diagnosis of multiple (mainly) infraten-
torial lesions includes demyelinating disorders, cerebral
angiitis of the CNS, lymphoma, and rare differential diag-
noses such as Erdheim–Chester disease (histiocytic dis-
ease with non-Langerhans cells) and chronic lymphocytic
inflammation with steroids to pontine perivascular
enhancement response to steroids (CLIPPERS).
Retrospectively, several red flags characterize this case.
Even under intensified immunotherapy, the patient only
showed temporary amelioration however persistent
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radiological disease activity. Because many inflammatory
and even infectious or neoplastic disorders may transiently
respond to immunosuppressive treatment, a recent consen-
sus on diagnostic criteria for neurosarcoidosis24 chose not
to include treatment response. Potential biomarkers of neu-
rosarcoidosis were unremarkable (ACE activity, sIL-2R),
however varying sensitivity and specificity due to extent of
organ involvement argues for use of these markers for
assessing disease activity, but not for diagnostic pur-
poses.25 Osteolytic bone lesions are typical for LCH, as
proliferating cells derive from myeloic progenitor cells of
the bone marrow.1 However, although less common, bone
involvement also occurs in up to 13% of sarcoidosis
patients.26 Unfortunately, by the time the rib lesion was
diagnosed, the patient refused to perform a (minimally
invasive) axillary biopsy, which retrospectively could have
provided precious diagnostic information. Furthermore,
along with progression of the disease, adherence to treat-
ment decreased, and additional functional neurological
components made clinical evaluation increasingly difficult,
which can also be considered as a red flag for the need of
diagnostic reevaluation.
The natural history of adults with CNS-LCH is very vari-
able and unpredictable. As in the case presented here, loca-
tion of the lesions and their inaccessibility to the diagnosis
without invasive interventions might cause delays in the
diagnosis and consequently in the beginning of treatment.
However, despite the delay, this patient survived 39 months
after the first diagnosis of intracerebral lesions in August
2014. The treatment received to treat neurosarcoidosis may
have played indeed a role, since many of the received drugs
are also recommended to treat CNS-LCH. Particularly inter-
esting is the fact that she received treatment with infliximab
for a total of 19 months.27 There are at least eight cases
reported in the literature describing an evolution benefit of
CNS-LCH under infliximab. Tumor necrosis factor (TNF)
inhibitor infliximab does not normally penetrate the CNS,
disruption of the blood–brain barrier can hypothetically
occur in CNS-LCH patients providing a portal of access to
these antibodies. In our case, none of these agents led to full
control of the disease, whether they acted by slowing disease
progression remains unclear.
Altogether this case underscores the need to obtain defi-
nitive pathological diagnosis of uncommon pathologies
before initiating or at least after failure of long-term immu-
nosuppressive treatment. In our case, the location of lesions
at sites difficult to biopsy and biopsy refusal for the osteo-
lytic lesion in the rib led to an extensive diagnostic delay.
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